Latest France News

Telix Pharmaceuticals reports a robust 53% revenue jump in Q3 2025 and raises its full-year guidance, underpinned by key reimbursement wins and expanding clinical programs.

Vulcan Energy has locked in a binding lithium hydroxide supply agreement with Glencore, completing the key offtake contracts needed to finance its Phase One Lionheart Project. This milestone positions Vulcan to advance construction and meet growing European EV battery demand.

Prescient Therapeutics has bolstered its cash reserves to $12.3 million following a $9.8 million capital raise, while progressing its PTX-100 cancer therapy through global Phase 2 trials with encouraging early lymphoma results.

Medical Developments International reported a strong start to FY26 with significant revenue growth driven by increased Penthrox volumes and pricing improvements in Australia, alongside steady European demand and progress on paediatric label approvals.

Brazilian Rare Earths has secured a decade-long heavy rare earth offtake deal with Carester, aligning Brazil’s high-grade resources with a leading European separation facility. This partnership also includes engineering support to accelerate BRE’s refinery development.

CLINUVEL Pharmaceuticals has presented compelling new case studies demonstrating the efficacy of SCENESSE® in treating vitiligo, showing significant and stable repigmentation in patients. These findings, shared at the EADV conference, hint at a potential breakthrough for a condition with limited treatment options.

Atlas Arteria has announced a 20.0 cents per stapled security distribution for the first half of 2025, with payments scheduled for early October. The distribution reflects the company’s ongoing commitment to delivering steady returns from its international toll road assets.

Paladin Energy Ltd has launched a significant A$300 million underwritten equity raising to advance its Patterson Lake South uranium project and support the ramp-up of its Langer Heinrich Mine, reinforcing its position in the global uranium market.

Cambium Bio has secured a strategic partnership with French pharmaceutical leader Benta SAS to commercialise its regenerative dry eye treatment, Elate Ocular, across Europe and the Middle East. This follows a second platelet-lysate licensing deal within days, underscoring growing industry confidence in Cambium’s platform.

Steadfast Group has reported a robust 17.2% increase in underlying net profit after tax for FY25, alongside a 14% rise in its fully franked final dividend, underpinned by both organic growth and strategic acquisitions.

SomnoMed has delivered a standout FY25 with revenue and EBITDA exceeding market expectations, driven by strong regional growth and operational improvements. The company is now expanding capacity and advancing its innovative Rest Assure device.

SomnoMed Limited reported a record FY25 with $111.5 million revenue and a return to positive EBITDA, marking a milestone of over one million patients treated globally. The company secured FDA clearance for its Rest Assure® compliance tracking device and provided optimistic guidance for FY26.